摘要
目的:观察多西他赛联合顺铂方案(DP方案)与伊立替康联合顺铂方案(IP方案)一线治疗晚期非小细胞肺癌(NSCLC)的近期疗效和不良反应。方法:采用前瞻性随机对照的临床研究设计,将65例经组织学或细胞学确诊的初治晚期NSCLC患者分为DP方案组和IP方案组,观察其近期有效率(RR)、疾病控制率(DCR)、疾病进展时间(TTP)、中位生存时间(MST)、1年生存率和不良反应。结果:DP方案组中,部分缓解(PR)11例,疾病稳定(SD)14例,疾病进展(PD)7例,RR为34.4%(11/32),DCR为78.1%(25/32);TTP为7.5个月,MST为12.5个月,1年生存率为53.1%(17/32)。IP方案组中,PR 10例,SD 15例,PD 8例,RR为30.3%(10/33),DCR为75.8%(25/33),TTP为6.9个月,MST为11.8个月,1年生存率为54.5%(18/33),上述临床疗效及生存期的比较,均无统计学差异(P>0.05)。两组患者的主要不良反应为血液学毒性、消化道反应和脱发,上述不良反应有统计学差异(P<0.05)。IP方案组腹泻的发生率高于DP方案组(P<0.05),而DP方案组粒细胞减少发生率高于IP方案组(P<0.05)。结论:DP方案和IP方案治疗晚期NSCLC疗效确切,不良反应均可耐受。
Objective：To prospectively evaluate the efficacy and toxicity of docetaxel plus cisplatin（DP regimen） compared with irinotecan plus cisplatin（IP regimen）as a first - line treatment for advanced non - small cell lung cancer（NSCLC）. Methods：A total of 65 patients were randomly assigned to two regimens. The response rate（RR）, disease control rate（DCR）,time to disease progression（TTP）,median survival time（MST）,1 - year survival rate, and side effects were observed. Results：Among the 32 cases of DP group,11 patients had PR,14 patients had SD and 7 patients had PD. The RR and DCR were 34. 4%（11 / 32）and 78. 1%（25 / 32）,respectively. The TTP was 7. 5 months,MST was 12. 5 months and 1 - year survival rate was 53. 1%（17 / 32）. Among 33 cases in the IP group,10 patients had PR,15 patients had SD and 8 patients had PD. The RR and DCR were 30. 3%（10 / 33）and 75. 8%（25 /33）,respectively. The TTP was 6. 9 months. MST was 11. 8 months and 1 - year survival rate was 54. 5%（18 / 33）. The comparison of the clinical curative effect and survival,had no statistical difference（P 〉 0. 05）. The main side effects of the two groups included hematologic toxicities,digestive tract reaction and hair loss. The adverse reactions had statistical difference（P 〈 0. 05）. The incidence of diarrhea in the IP group was significantly higher than that in the DP group（P 〈 0. 05）,but the incidence of leukopenia in the DP group was significantly higher than that in the IP group（P 〈 0. 05）. Conclusion：Two regimens have similar efficacy as a first - line treatment for advanced NSCLC. The major toxicities of the two regimens are well tolerable.
出处
《现代肿瘤医学》
CAS
2016年第24期3947-3950,共4页
Journal of Modern Oncology
关键词
非小细胞肺癌
多西他赛
伊立替康
顺铂
non - small cell lung carcinoma
docetaxel
irinotecan
cisplatin
作者简介
吕春霞（1976-）,女,陕西汉阴人,主治医师,主要从事肿瘤内科临床工作.E-mail：1306432874@qq.com
